US FTC orders Aurobindo to divest four drug products to complete Lannett deal
Aurobindo Pharma Limited will be required to divest four drug products in order to complete its $250 million acquisition of Lannett Company, as ordered by the US Federal Trade Commission. The...To view the full article, register now.
Already a subscriber? Click here to view full article